Interpace Biosciences Inc Stock Price, News & Analysis

Interpace Biosciences reported Q3 2021 revenue of $9.5 million, a 15% increase year-over-year, with year-to-date revenue reaching $30.5 million, up 34%. The company achieved record cash collections for the second consecutive quarter and improved liquidity with a $7.5 million credit facility from Comerica Bank and a new $8 million term loan from BroadOak Fund. The firm plans a $30 million Rights Offering to maintain shareholder ownership. Despite a decline in pharma services, gross profit rose to 44% year-to-date, indicating strong operational performance.

Interpace Biosciences (OTCQX: IDXG) has secured an $8 million term loan from BroadOak Fund V, L.P. The loan aims to repay existing short-term promissory notes to private equity stockholders, enhancing the Company's liquidity without equity dilution. Coupled with a $7.5 million revolving credit facility from Comerica Bank, this financing strategy is aimed at improving operational flexibility. The BroadOak Loan has a three-year maturity and is secured by the Company's assets, emphasizing BroadOak's confidence in Interpace's growth trajectory.

Interpace Biosciences announced the granting of US Patent 11,143,657 for its PancraGEN technology, aimed at improving the diagnosis and management of pancreatic cysts. This patent enhances the molecular diagnostic capabilities of PancraGEN^®, which has been used on over 40,000 cyst samples, boasting a 90% accuracy in risk assessment. The technology aims to better handle pancreatic cancer, a leading cause of cancer deaths in the U.S. This patent solidifies Interpace’s role in personalized medicine, targeting effective cancer diagnosis and treatment solutions.

Interpace Biosciences (OTCQX: IDXG) announced on October 21, 2021 that the U.S. Patent and Trademark Office granted it a patent (U.S. PTO Number 11,118,231 B2) for using microRNAs in distinguishing benign from malignant thyroid neoplasms. This patent enhances the intellectual property portfolio of the company, particularly for its ThyraMIR® microRNA Classifier, which works alongside the ThyGeNEXT® test. This innovation aims to improve patient care by reducing unnecessary thyroid surgeries through actionable results from microRNA expression levels.

Interpace Biosciences (OTCQX: IDXG) announced a new $7.5 million revolving credit facility with Comerica Bank, set to mature on September 30, 2023. The financing is based on 80% of eligible accounts receivable, with additional availability of $2 million. The credit facility's interest rate is prime plus 0.5%. CEO Thomas Burnell highlighted the facility's potential to support business growth and enhance diagnostic capabilities in healthcare. The bank expressed support for Interpace's mission in cancer diagnostics through this partnership.

Interpace Biosciences reported Q2 2021 net revenue of $11.2 million, a 105% increase year-over-year, marking its highest revenue quarter. The company is approaching EBITDA breakeven on higher clinical volumes and improved gross profit margins, which rose to 48% from 29%. Cash collections exceeded $11 million in Q2, contributing to a reduced loss from continuing operations of $(3.4) million. The company aims for full-year revenue growth of 35%, despite experiencing a decline in pharma services volume amidst the lab consolidation.

Interpace Pharma Solutions, a subsidiary of Interpace Biosciences (OTCQX: IDXG), announced the launch of its Digital Spatial Profiling services using the GeoMx® testing platform. This platform integrates high-throughput expression analysis with IHC/FISH capabilities, allowing precise measurement of proteins and nucleic acids in tissue samples. The technology aims to enhance biomarker discovery and cancer research. Thomas Burnell, President and CEO, emphasized that GeoMx® complements existing technologies, enhancing their service offerings for personalized medicine.

Interpace Biosciences reported a record Q1 revenue of $9.8 million, driven by increased clinical service volume and improved reimbursement rates. The company anticipates Q2 revenue exceeding $11 million and is on track for 35% annual growth. Notably, their gross profit margin improved to 46%, and losses from continuing operations decreased significantly. Recent agreements with Blue Cross Blue Shield also enhance coverage for key tests, potentially boosting future revenues. The company aims for EBITDA breakeven by Q3 2021.

Interpace Biosciences (OTCQX: IDXG) announced that eviCore Healthcare, a Cigna subsidiary, will include positive coverage for its molecular tests, ThyGeNEXT® and ThyraMIR®, in updated laboratory management guidelines. This change affects 27 health plans and covers around 100 million lives, effective July 1, 2021. The tests are recognized for reducing unnecessary invasive procedures and improving healthcare cost-efficiency. Interpace aims to enhance personalized medicine with multiple clinical diagnostic tests and services.